1Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
3Remme WJ.Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease:randomized,double-blind,placebo-controlled,multicentre trial:the EUROPA study[J].Lancet,2003,362(9386):782.
4Daly CA,Fox KM,Remme WJ,et al.The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study:results from the PERSUADE substudy[J].Eur Heart J,2005,26(14):1 369.
5Cleland JG,Tendera M,Adamus J,et al.The perindopril in elderly people with chronic heart failure(PEP-CHF)study[J].Eur Heart J,2006,27(19):2 338.
6Bertrand ME,Ferrari R,Remme WJ,et al.Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality inpatients with coronary artery disease.Post hoc analysis of the EUROPA study[J].Am Heart J,2010,159(5):795.
7Fox KM,Bertrand ME,Remme WJ,et al.Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease[J].Am Heart J,2007,153(4):629.
8Bertrand ME,Remme WJ,Fox KM,et al.Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved leftventricular function[J].Int J Cardiol,2007,121(1):57.
9Fa tima Ceia.A comparative study of the first dose hypotensive effects of captopril and perindopril in patients with heart failure[J].Cardiovasc Drugs Ther,2001,15(6):501.
